// App-Quantinova.ai

1342 : Quality Improvement: Communicating Risk Regarding JAK Inhibitor Use in Rheumatology Patients

Researchers

Presenter

  • Reid Weisberg

Principal Investigators

  • Brett Capel

  • Annabelle Guo

  • Komal Patel

  • Rashmi Arora

  • Swathi Reddy

  • Una Makris

Medical Centers

  • The University of Texas Southwestern Medical Center, Dallas, TX

  • Dallas Veterans Affairs Medical Center and University of Texas Southwestern Medical Center, Dallas, TX

  • Dallas VA Medical Center / University of Texas Southwestern Medical Center, Colleyville, TX

  • UT Southwestern Medical Ctr at Dallas, Dallas, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

  • Solid malignancies

  • Acquired immunodeficiency syndrome

  • Gastrointestinal stromal tumor

Biomarkers

  • Janus kinase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved